In the third quarter of 2019 HAEMATO AG, Berlin (ISIN: DE0006190705), achieved IFRS consolidated revenues of EUR 47.8 million. In the considered period from January to Sep-tember 2019 the sales totaled EUR 141.8 million (previous year: EUR 212.8 million). The EBITDA amounts to EUR 1.6 million (previous year: EUR 6.4 million). The main reason for the decrease of the EBITDA can be found in a decline in sales compared to the same period of the previous year. In the third quarter of 2019, revenues increased by almost 5% compared to the second quarter; the October sales also increased compared to the previous month. The Executive Board consideres both facts as indicators for positive development in the last quarter of 2019.
In the third quarter of 2019, the dividend distribution of EUR 0.10 per share (EUR 2.287 million) was approved by the Annual General Meeting held on July 10, 2019. Despite the payout to the shareholders in July 2019, the equity ratio of the HAEMATO Group amounted to 62.8 % as of 30.09.2019.
The HAEMATO Group has established itself on the market as a reliable supplier of specialty pharmaceuticals. Our specialization in medicines for the treatment of chronic diseases leads us to anticipate above-average growth in the future due to demographic developments.
The Executive Board seeks to optimize core business processes and instroduce new products and product groups in order to broaden the company’s portfolio.
HAEMATO AG, founded in 1993, is a pharmaceutical company focusing on the growing markets of high-priced specialty pharmaceuticals in the indication areas of oncology and HIV as well as other chronic diseases.
HAEMATO AG is listed on the Basic Board (Open Market) of the Frankfurt Stock Exchange. Key figures on the HAEMATO AG share:
Subscribed capital: EUR 22,867,154
Listed class of shares: bearer ordinary shares
Stock exchange code: HAE